First-in-Human Two-Part Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma

Clinical Trial Grant

Duke Scholars

Principal Investigator Cristina Gasparetto Medicine, Hematologic Malignancies and Cellular Therapy

Awarded By

AbbVie Inc.

Start Date

September 26, 2022

End Date

September 30, 2027

Awarded By

AbbVie Inc.

Start Date

September 26, 2022

End Date

September 30, 2027